Published in Am J Psychiatry on October 01, 2003
Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med (2011) 2.43
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med (2010) 2.40
Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry (2010) 2.06
Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med (2007) 2.02
Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol (2009) 1.65
How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology (2008) 1.56
Depression, antidepressant medications, and risk of Clostridium difficile infection. BMC Med (2013) 1.54
Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase. Biol Psychiatry (2012) 1.27
Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer (2008) 1.22
Principles for evidence-based drug formulary policy. J Gen Intern Med (2005) 1.22
Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry (2009) 1.21
Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One (2008) 1.21
Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2012) 1.19
Personalized medicine in psychiatry: problems and promises. BMC Med (2013) 1.09
Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease. Curr Opin Pharmacol (2011) 1.04
Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin Neurosci (2010) 1.03
Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). Br J Clin Pharmacol (2004) 1.02
Nonepileptic seizures treatment workshop summary. Epilepsy Behav (2006) 1.02
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse (2009) 1.02
Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction. Drug Metab Dispos (2011) 0.98
Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. Int J Neuropsychopharmacol (2008) 0.98
Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev (2011) 0.98
Clinical use of pharmacogenomic tests in 2009. Clin Biochem Rev (2009) 0.95
Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci (2005) 0.93
The promise and reality of pharmacogenetics in psychiatry. Psychiatr Clin North Am (2010) 0.92
A meta-analysis of the effects of the 5-hydroxytryptamine transporter gene-linked promoter region polymorphism on susceptibility to lifelong premature ejaculation. PLoS One (2013) 0.89
Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol (2007) 0.88
Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatr Dis Treat (2005) 0.86
From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology (Berl) (2004) 0.85
Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report. J Clin Psychopharmacol (2010) 0.85
Pharmacogenetics in mood disorder. Curr Opin Psychiatry (2005) 0.84
Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur Arch Psychiatry Clin Neurosci (2008) 0.84
FKBP5 polymorphisms and antidepressant response in geriatric depression. Am J Med Genet B Neuropsychiatr Genet (2010) 0.83
Pharmacogenetics of antidepressants. Front Pharmacol (2011) 0.82
ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression. Pharmacogenomics J (2014) 0.82
Cytochrome P450 genotyping and antidepressants. BMJ (2007) 0.81
Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors. J Neural Transm (Vienna) (2014) 0.80
Pharmacogenetic profiling in the treatment of heart disease. Transl Res (2009) 0.79
Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response. Genome Med (2012) 0.78
Regulation of rat cortical 5-hydroxytryptamine2A receptor-mediated electrophysiological responses by repeated daily treatment with electroconvulsive shock or imipramine. Eur Neuropsychopharmacol (2008) 0.78
DBH gene as predictor of response in a cocaine vaccine clinical trial. Neurosci Lett (2013) 0.78
Genetics and psychopharmacology: prospects for individualized treatment. Essent Psychopharmacol (2005) 0.77
The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial. Psychiatr Genet (2013) 0.77
Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders. J Neural Transm (Vienna) (2016) 0.76
CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry Investig (2013) 0.76
Evaluating the role of serotonin on neuropsychological function after breast cancer using acute tryptophan depletion. Biol Res Nurs (2010) 0.76
Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet (2015) 0.76
The silver lining of recent effectiveness trials. World Psychiatry (2009) 0.75
Genetics in pharmacokinetics? Am J Psychiatry (2004) 0.75
Neuroscience and clinical practice: applying pharmacogenomics in psychiatry. Psychiatry (Edgmont) (2006) 0.75
Cortical 5-hydroxytryptamine2A-receptor mediated excitatory synaptic currents in the rat following repeated daily fluoxetine administration. Neurosci Lett (2008) 0.75
Pharmacogenomic testing: aiding in the management of psychotropic therapy for adolescents with autism spectrum disorders. Pharmgenomics Pers Med (2017) 0.75
Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci (2007) 19.58
Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol Psychiatry (2007) 9.08
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology (2006) 3.80
Recruiting and retaining future generations of physician scientists in mental health. Arch Gen Psychiatry (2002) 3.69
Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc Natl Acad Sci U S A (2009) 3.49
The future of psychiatry as clinical neuroscience. Acad Med (2009) 3.31
Failure of anterior cingulate activation and connectivity with the amygdala during implicit regulation of emotional processing in generalized anxiety disorder. Am J Psychiatry (2010) 3.14
Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. Arch Gen Psychiatry (2009) 2.67
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol (2007) 2.60
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A (2003) 2.56
Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry (2003) 2.45
Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry (2007) 2.25
On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J Clin Endocrinol Metab (2005) 2.25
An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry (2002) 2.14
Common abnormalities and disorder-specific compensation during implicit regulation of emotional processing in generalized anxiety and major depressive disorders. Am J Psychiatry (2011) 2.01
Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res (2005) 1.95
Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology (2006) 1.86
Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry (2002) 1.65
Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. Proc Natl Acad Sci U S A (2013) 1.63
A word to the wise about ketamine. Am J Psychiatry (2014) 1.61
Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav (2003) 1.60
Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull (2002) 1.56
Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry (2002) 1.55
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry (2007) 1.54
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry (2004) 1.54
International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials (2011) 1.46
Maternal mediation, stress inoculation, and the development of neuroendocrine stress resistance in primates. Proc Natl Acad Sci U S A (2006) 1.45
Prospective investigation of stress inoculation in young monkeys. Arch Gen Psychiatry (2004) 1.45
Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol (2004) 1.41
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry (2007) 1.40
Extended treatment with bupropion SR for cigarette smoking cessation. J Consult Clin Psychol (2006) 1.40
Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry (2002) 1.37
Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. Psychoneuroendocrinology (2005) 1.31
Regional analysis of hippocampal activation during memory encoding and retrieval: fMRI study. Hippocampus (2003) 1.29
National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry (2002) 1.29
Mild early life stress enhances prefrontal-dependent response inhibition in monkeys. Biol Psychiatry (2005) 1.28
Current issues in the classification of psychotic major depression. Schizophr Bull (2007) 1.22
Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry (2006) 1.20
Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex. J Psychiatr Res (2013) 1.20
Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet (2011) 1.20
Chronic pain and major depressive disorder in the general population. J Psychiatr Res (2010) 1.15
The neuropsychological profile of psychotic major depression and its relation to cortisol. Biol Psychiatry (2006) 1.14
Developing novel treatments for mood disorders: accelerating discovery. Biol Psychiatry (2002) 1.13
Extended cognitive behavior therapy for cigarette smoking cessation. Addiction (2008) 1.13
The efficacy of antidepressants in the treatment of late-life depression. J Clin Psychopharmacol (2005) 1.08
Prefrontal plasticity and stress inoculation-induced resilience. Dev Neurosci (2009) 1.08
Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol (2007) 1.07
Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul (2010) 1.07
Developmental cascades linking stress inoculation, arousal regulation, and resilience. Front Behav Neurosci (2009) 1.06
The Career Development Institute for Psychiatry: an innovative, longitudinal program for physician-scientists. Acad Psychiatry (2009) 1.05
Stress coping stimulates hippocampal neurogenesis in adult monkeys. Proc Natl Acad Sci U S A (2010) 1.05
Preliminary evidence that plasma oxytocin levels are elevated in major depression. Psychiatry Res (2010) 1.03
Animal models of early life stress: implications for understanding resilience. Dev Psychobiol (2010) 1.01
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. J Clin Psychiatry (2002) 1.01
Gene expression changes in the prefrontal cortex, anterior cingulate cortex and nucleus accumbens of mood disorders subjects that committed suicide. PLoS One (2012) 1.01
Social phobia and depression: prevalence and comorbidity. J Psychosom Res (2010) 1.00
Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. ScientificWorldJournal (2010) 0.99
Preliminary evidence that hippocampal volumes in monkeys predict stress levels of adrenocorticotropic hormone. Biol Psychiatry (2007) 0.99
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry (2007) 0.99
Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. Am J Psychiatry (2008) 0.96
Early life stress and novelty seeking behavior in adolescent monkeys. Psychoneuroendocrinology (2007) 0.95
Aging and the role of the HPA axis and rhythm in sleep and memory-consolidation. Am J Geriatr Psychiatry (2005) 0.95
Experience-dependent asymmetric variation in primate prefrontal morphology. Behav Brain Res (2002) 0.94
Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function. Psychoneuroendocrinology (2009) 0.93
Cognitive correlates of white matter growth and stress hormones in female squirrel monkey adults. J Neurosci (2004) 0.93
Aberrant brain activation during a working memory task in psychotic major depression. Am J Psychiatry (2010) 0.93
Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology (2004) 0.93
Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. J Psychiatr Res (2004) 0.92
The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls. Psychoneuroendocrinology (2007) 0.90
Process irregularity of cortisol and adrenocorticotropin secretion in men with major depressive disorder. Psychoneuroendocrinology (2004) 0.90
An examination of 26,168 Hamilton Depression Rating Scale scores administered via interactive voice response across 17 randomized clinical trials. J Clin Psychopharmacol (2006) 0.90
Withdrawal symptoms over time among adolescents in a smoking cessation intervention: do symptoms vary by level of nicotine dependence? Addict Behav (2009) 0.89
Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry (2002) 0.89
Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. Addiction (2010) 0.89
Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. J Clin Psychiatry (2003) 0.89
ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics (2010) 0.89
Evidence for transcriptional factor dysregulation in the dorsal raphe nucleus of patients with major depressive disorder. Front Neurosci (2012) 0.88
Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res (2008) 0.88
HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology (2004) 0.88
Pretreatment cortisol levels predict posttreatment outcomes among older adults with depression in cognitive behavioral therapy. Psychiatry Res (2013) 0.88
Social stress-related behavior affects hippocampal cell proliferation in mice. Physiol Behav (2006) 0.88
From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr (2005) 0.88
Using treatment process data to predict maintained smoking abstinence. Am J Health Behav (2010) 0.88
Relating semantic and episodic memory systems. Brain Res Cogn Brain Res (2002) 0.87
Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial. Trials (2013) 0.87
A pilot study of the phase angle between cortisol and melatonin in major depression - a potential biomarker? J Psychiatr Res (2009) 0.87
Monoamine oxidase and catechol-o-methyltransferase enzyme activity and gene expression in response to sustained glucocorticoids. Psychoneuroendocrinology (2005) 0.87
Detecting psychotic major depression using psychiatric rating scales. J Psychiatr Res (2005) 0.87
Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. J Mol Neurosci (2002) 0.86
Animal models of early life stress: Implications for understanding resilience. Dev Psychobiol (2010) 0.86
A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol (2003) 0.86
Application of microarray technology in primate behavioral neuroscience research. Methods (2006) 0.86
The acute and post-discontinuation effects of a glucocorticoid receptor (GR) antagonist probe on sleep and the HPA axis in chronic insomnia: a pilot study. J Clin Sleep Med (2008) 0.86
Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry (2007) 0.85
The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biol Psychiatry (2003) 0.84
The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. Psychoneuroendocrinology (2012) 0.84